↓ Skip to main content

Dove Medical Press

Article Metrics

Spotlight on frovatriptan: a review of its efficacy in the treatment of migraine

Overview of attention for article published in Drug Design, Development and Therapy, October 2016
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Above-average Attention Score compared to outputs of the same age and source (59th percentile)

Mentioned by

twitter
2 tweeters
video
1 video uploader

Readers on

mendeley
21 Mendeley
Title
Spotlight on frovatriptan: a review of its efficacy in the treatment of migraine
Published in
Drug Design, Development and Therapy, October 2016
DOI 10.2147/dddt.s105932
Pubmed ID
Authors

Gianni Allais, Chiara Benedetto

Abstract

Migraine is a common neurovascular disorder, affecting millions of people worldwide. Current guidelines recommend triptans as first-line treatment for moderate-to-severe migraine attacks. Frovatriptan is a second-generation triptan with a longer terminal elimination half-life in blood than other triptans (~26 hours). Three double-blind, randomized crossover preference studies have been recently conducted, assessing efficacy and safety of frovatriptan versus rizatriptan, zolmitriptan, and almotriptan, respectively. Frovatriptan showed favorable tolerability and sustained effect, with a significantly lower rate of relapse over 48 hours versus the other triptans. These findings were confirmed in a series of analyses of patient subsets from the three studies, including patients with menstrually related and oral contraceptive-induced migraine, hypertension, obesity, weekend migraine, as well as patients with migraine with aura. In all patient subsets analyzed, lower headache recurrence rates were observed versus the comparator triptans, indicating a more sustained pain-relieving effect on migraine symptoms. A further randomized, double-blind study demonstrated that frovatriptan given in combination with the fast-acting cyclooxygenase inhibitor dexketoprofen provided improved migraine pain-free activity at 2 hours, and gave more sustained pain-free activity at 24 hours, versus frovatriptan alone. These benefits were observed both when the combination was administered early (<1 hour after symptom onset) or late (>1 hour after onset). Different pharmacokinetic, but synergistic, properties between frovatriptan and dexketoprofen may make the combination of these agents particularly effective in migraine treatment, with rapid onset of action and sustained effect over 48 hours. These benefits, together with potential cost-effectiveness advantages versus other triptans could drive selection of the most appropriate treatment for acute migraine attacks.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 21 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 5 24%
Student > Doctoral Student 4 19%
Researcher 3 14%
Other 2 10%
Student > Master 2 10%
Other 1 5%
Unknown 4 19%
Readers by discipline Count As %
Medicine and Dentistry 9 43%
Agricultural and Biological Sciences 3 14%
Nursing and Health Professions 2 10%
Pharmacology, Toxicology and Pharmaceutical Science 1 5%
Neuroscience 1 5%
Other 1 5%
Unknown 4 19%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 October 2016.
All research outputs
#7,943,948
of 12,662,735 outputs
Outputs from Drug Design, Development and Therapy
#560
of 1,343 outputs
Outputs of similar age
#146,758
of 266,019 outputs
Outputs of similar age from Drug Design, Development and Therapy
#20
of 59 outputs
Altmetric has tracked 12,662,735 research outputs across all sources so far. This one is in the 23rd percentile – i.e., 23% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,343 research outputs from this source. They receive a mean Attention Score of 4.4. This one is in the 48th percentile – i.e., 48% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 266,019 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 35th percentile – i.e., 35% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 59 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 59% of its contemporaries.